A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Mar 2025, none posted yet
Counts until it's fixed
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 228 (final count)
- Started
- Dec 15, 2020
- Main results expected
- Mar 18, 2025
- Fully finished
- Oct 27, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of Participants with Dose Limiting Toxicity (DLT)
Measured over: Approximately 5 years 10 months
Part 1: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Measured over: Approximately 5 years 10 months
Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability
Measured over: Approximately 5 years 10 months
Part 2: Number of Participants with Adverse Events and SAEs by Severity
Measured over: Approximately 5 years 10 months
Part 3: Overall Response Rate (ORR)
Measured over: Approximately 5 years 10 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-03-18, no fading
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04586426 · record last updated 2026-01-16 · checked 2026-11-09 15:47 UTC